Haemonetics (HAE) stock experienced a sharp decline, plummeting 5.04% during intraday trading on Friday. The significant drop reflects heightened selling pressure on the healthcare company's shares.

The sell-off appears to be driven by a wave of analyst actions published earlier in the session. Citi lowered its price target on Haemonetics to $75 from $88, while maintaining a Neutral rating. Similarly, Mizuho Securities cut its target price to $80 from $90. Additionally, Baird reduced its price target to $81 from $99, though it kept an Outperform rating on the shares. These downward revisions in price targets from multiple firms likely contributed to negative investor sentiment and the stock's decline.